402 related articles for article (PubMed ID: 36293274)
1. Impact of
Meoli A; Eickmeier O; Pisi G; Fainardi V; Zielen S; Esposito S
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293274
[TBL] [Abstract][Full Text] [Related]
2. Treating the Underlying Cystic Fibrosis Transmembrane Conductance Regulator Defect in Patients with Cystic Fibrosis.
Cuyx S; De Boeck K
Semin Respir Crit Care Med; 2019 Dec; 40(6):762-774. PubMed ID: 31659727
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule drugs for cystic fibrosis: Where are we now?
Laselva O; Guerra L; Castellani S; Favia M; Di Gioia S; Conese M
Pulm Pharmacol Ther; 2022 Feb; 72():102098. PubMed ID: 34793977
[TBL] [Abstract][Full Text] [Related]
4. Emerging Concepts in Defective Macrophage Phagocytosis in Cystic Fibrosis.
Jaganathan D; Bruscia EM; Kopp BT
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887098
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of cystic fibrosis treatment.
Carter SC; McKone EF
Pharmacogenomics; 2016 Aug; 17(13):1453-63. PubMed ID: 27490265
[TBL] [Abstract][Full Text] [Related]
6. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
7. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory Activity of Epithelial Stem Cell Variants from Cystic Fibrosis Lungs Is Not Resolved by CFTR Modulators.
Wang S; Niroula S; Hoffman A; Khorrami M; Khorrami M; Yuan F; Gasser GN; Choi S; Liu B; Li J; Metersky ML; Vincent M; Crum CP; Boucher RC; Karmouty-Quintana H; Huang HJ; Sheshadri A; Dickey BF; Parekh KR; Engelhardt JF; McKeon FD; Xian W
Am J Respir Crit Care Med; 2023 Nov; 208(9):930-943. PubMed ID: 37695863
[No Abstract] [Full Text] [Related]
9. Small molecule modulators of cystic fibrosis transmembrane conductance regulator (CFTR): Structure, classification, and mechanisms.
Cao L; Wu Y; Gong Y; Zhou Q
Eur J Med Chem; 2024 Feb; 265():116120. PubMed ID: 38194776
[TBL] [Abstract][Full Text] [Related]
10. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
Solomon GM; Marshall SG; Ramsey BW; Rowe SM
Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
[TBL] [Abstract][Full Text] [Related]
11. Optimal complement-mediated phagocytosis of Pseudomonas aeruginosa by monocytes is cystic fibrosis transmembrane conductance regulator-dependent.
Van de Weert-van Leeuwen PB; Van Meegen MA; Speirs JJ; Pals DJ; Rooijakkers SH; Van der Ent CK; Terheggen-Lagro SW; Arets HG; Beekman JM
Am J Respir Cell Mol Biol; 2013 Sep; 49(3):463-70. PubMed ID: 23617438
[TBL] [Abstract][Full Text] [Related]
12. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist.
Lee SE; Farzal Z; Daniels MLA; Thorp BD; Zanation AM; Senior BA; Ebert CS; Kimple AJ
Am J Rhinol Allergy; 2020 Jul; 34(4):573-580. PubMed ID: 32168995
[TBL] [Abstract][Full Text] [Related]
13. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls.
Bell SC; De Boeck K; Amaral MD
Pharmacol Ther; 2015 Jan; 145():19-34. PubMed ID: 24932877
[TBL] [Abstract][Full Text] [Related]
14. Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations.
Lara-Reyna S; Holbrook J; Jarosz-Griffiths HH; Peckham D; McDermott MF
Cell Mol Life Sci; 2020 Nov; 77(22):4485-4503. PubMed ID: 32367193
[TBL] [Abstract][Full Text] [Related]
15. The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis.
Harvey C; Weldon S; Elborn S; Downey DG; Taggart C
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35408875
[TBL] [Abstract][Full Text] [Related]
16. Discovery of CFTR modulators for the treatment of cystic fibrosis.
Lopes-Pacheco M; Pedemonte N; Veit G
Expert Opin Drug Discov; 2021 Aug; 16(8):897-913. PubMed ID: 33823716
[TBL] [Abstract][Full Text] [Related]
17. Personalized medicine in CF: from modulator development to therapy for cystic fibrosis patients with rare CFTR mutations.
Harutyunyan M; Huang Y; Mun KS; Yang F; Arora K; Naren AP
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L529-L543. PubMed ID: 29351449
[TBL] [Abstract][Full Text] [Related]
18. Cystic fibrosis transmembrane conductance regulator (CFTR) modulators have differential effects on cystic fibrosis macrophage function.
Zhang S; Shrestha CL; Kopp BT
Sci Rep; 2018 Nov; 8(1):17066. PubMed ID: 30459435
[TBL] [Abstract][Full Text] [Related]
19. One Size Does Not Fit All: The Past, Present and Future of Cystic Fibrosis Causal Therapies.
Ensinck MM; Carlon MS
Cells; 2022 Jun; 11(12):. PubMed ID: 35740997
[TBL] [Abstract][Full Text] [Related]
20. Elevated Mirc1/Mir17-92 cluster expression negatively regulates autophagy and CFTR (cystic fibrosis transmembrane conductance regulator) function in CF macrophages.
Tazi MF; Dakhlallah DA; Caution K; Gerber MM; Chang SW; Khalil H; Kopp BT; Ahmed AE; Krause K; Davis I; Marsh C; Lovett-Racke AE; Schlesinger LS; Cormet-Boyaka E; Amer AO
Autophagy; 2016 Nov; 12(11):2026-2037. PubMed ID: 27541364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
